keyword
MENU ▼
Read by QxMD icon Read
search

Crohn' disease

keyword
https://www.readbyqxmd.com/read/29045603/ustekinumab-drug-levels-in-maternal-and-cord-blood-in-a-woman-with-crohn-s-disease-treated-until-33-weeks-gestation
#1
Catherine R Rowan, Garret Cullen, Hugh E Mulcahy, Denise Keegan, Kathryn Byrne, Deirdre J Murphy, Juliette Sheridan, Glen A Doherty
A 35-year old woman with ileocolonic, perianal and vulval Crohn's disease was treated with subcutaneous ustekinuamb (USK) throughout pregnancy. Dose intervals were shortened from 6-weekly to 4-weekly to maintain clinical remission. The last dose of USK was administered at 33 weeks gestation and a healthy baby boy was delivered by caesarean section at 37 weeks. Maternal trough USK levels remained stable during pregnancy. Cord blood USK levels were nearly two-fold higher than contemporaneous maternal serum levels...
October 16, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29045353/impaired-il-10-receptor-mediated-suppression-in-monocyte-from-patients-with-crohn-s-disease
#2
Moran Y Nunberg, Lael Werner, Uri Kopylov, Yael Haberman, Avishay Lahad, Batia Weiss, Dror S Shouval
OBJECTIVES: Interleukin-10 (IL-10) is an immunoregulatory cytokine that has a central role in suppressing pro-inflammatory responses. Patients with deleterious mutations in IL-10 or IL-10 receptor (IL-10R) genes develop severe colitis and perianal disease in the first months of life. Whether IL-10R expression and signaling in pediatric- or adult-onset Crohn's disease (CD) are altered is unknown. The objective of this study was to characterize IL-10R expression and IL-10R-mediated suppression in patients with CD...
October 17, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29045262/ibd-live-series-case-8-treatment-options-for-refractory-esophageal-crohn-s-disease-and-hidradenitis-suppurativa-erratum
#3
(no author information available yet)
No abstract text is available yet for this article.
November 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29044887/quantitative-mapping-of-genetic-similarity-in-human-heritable-diseases-by-shared-mutations
#4
Huiying Zhao, Yuedong Yang, Yutong Lu, Matthew Mort, David N Cooper, Zhiyi Zuo, Yaoqi Zhou
Many genetic diseases exhibit considerable epidemiological comorbidity and common symptoms, which provokes debate about the extent of their etiological overlap. The rapid growth in the number of known disease-causing mutations in the Human Gene Mutation Database (HGMD) has allowed us to characterise genetic similarities between diseases by ascertaining the extent to which identical genetic mutations are shared between diseases. Using this approach, we show that 41.6% of disease pairs in all possible pairs (42, 083) exhibit a significant sharing of mutations (P-value < 0...
October 17, 2017: Human Mutation
https://www.readbyqxmd.com/read/29044604/epstein-barr-virus-positive-mucocutaneous-ulcer-in-a-background-of-crohn-s-disease-and-waldenstr%C3%A3-m-macroglobulinemia-a-case-report-highlighting-diagnostic-pitfalls
#5
Larissa Sena Teixeira Mendes, James McCaul, Andrew Wotherspoon, Ayoma D Attygalle
A specialist haematopathology opinion was sought on a left palatine tonsillar excision biopsy performed for suspected carcinoma. The patient, a 72-year old male, presented with oropharyngeal dysphagia in May 2015 and was diagnosed with hypertrophic, ulcerated lichen planus on an incision biopsy of a white patch on the posterior third of the tongue. Topical steroids were commenced with clinical improvement. This article is protected by copyright. All rights reserved.
October 16, 2017: Histopathology
https://www.readbyqxmd.com/read/29043862/the-potential-role-of-fdg-pet-ct-in-the-characterization-of-the-activity-of-crohn-s-disease-staging-follow-up-and-prognosis-estimation-a-pilot-study
#6
Károly Palatka, Sándor Kacska, Szilvia Lovas, Ildikó Garai, József Varga, László Galuska
OBJECTIVES: FDG PET-CT is a global, noninvasive, sensitive method to determine the location and activity of inflammatory lesions. Segmental FDG uptake is proportional with immune cell infiltration of bowel. Our aim was to evaluate prospectively the role of PET in patients with active Crohn's disease (CD) before and after one year's biological therapy, and to compare simple endoscopic score for CD (SES-CD), CD activity index (CDAI) and global PET scores. We also analyzed the prognostic value of initial PET scores...
October 18, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/29043578/duodenal-crohn-s-disease-a-diagnostic-conundrum
#7
Amy L Lightner, Joel G Fletcher
Gastroduodenal Crohn's disease is rare as most often the disease is found in the terminal ileum and colon rather than the upper gastrointestinal tract. The most common phenotype is stricturing disease which can lead to obstructive-like symptoms. Medical treatment options include proton pump inhibitors and biologic therapy. Endoscopic and surgical intervention may be needed to relieve the obstructive-like symptoms from the stricturing phenotype.
October 17, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/29043290/checkpoint-inhibitor-induced-colitis-a-new-type-of-inflammatory-bowel-disease
#8
Madeline Bertha, Emanuelle Bellaguara, Timothy Kuzel, Stephen Hanauer
Checkpoint inhibitors are immune-stimulatory antibodies that have transformed the management and prognosis of individuals with metastatic melanoma and other cancers. Checkpoint inhibitor-induced colitis is an increasingly recognized immune-related adverse event that shares many of the same phenotypical, serological, and histological characteristics of both Crohn's disease and ulcerative colitis, suggesting that checkpoint inhibitor-induced colitis may represent a new inflammatory bowel disease phenotype. We report a 73-year-old man with metastatic melanoma who developed ipilimumab-induced colitis with subsequent transformation to Crohn?s colitis-like phenotype after the addition of pembrolizumab...
2017: ACG Case Reports Journal
https://www.readbyqxmd.com/read/29042094/ustekinumab-to-treat-crohn-s-disease
#9
Javier P Gisbert, María Chaparro
Ustekinumab is a monoclonal antibody directed against the p40 subunit, which is part of interleukins IL-12 and IL-23. The efficacy of ustekinumab versus placebo in terms of clinical response and remission of induction has been shown in phase3 clinical trials. When used as subcutaneous maintenance therapy, the therapeutic benefit of ustekinumab over placebo has been confirmed in both clinical response and remission in patients who have responded clinically to induction therapy. In addition, ustekinumab has demonstrated an improvement in mucosal healing parameters...
October 14, 2017: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/29038892/-pityriasis-amiantacea-and-folliculitis-decalvans-an-unusual-manifestation-associated-with-antitumor-necrosis-factor-%C3%AE-therapy
#10
M Zamperetti, B Zelger, R Höpfl
We report on a 21-year-old woman with a 3-year history of crusts and erosions on her scalp that had appeared after starting treatment with adalimumab due to Crohn's disease. By clinicopathological correlation pityriasis amiantacea with underlying folliculitis decalvans was diagnosed. Topical and systemic antibiotic treatment showed rapid response. The occurrence of pityriasis amiantacea in folliculitis decalvans associated with tumor necrosis factor (TNF)-α inhibitor therapy is remarkable and highlights the ambivalent role of TNF-α in diseases with immunological dysfunctions in combination with infections...
October 16, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/29038856/comparison-of-diagnostic-performance-between-1-millisievert-ct-enterography-and-half-standard-dose-ct-enterography-for-evaluating-active-inflammation-in-patients-with-crohn-s-disease
#11
Jung Hee Son, Seung Ho Kim, Een Young Cho, Kyeong Hwa Ryu
PURPOSE: To compare the diagnostic performance of CT enterography (CTE) images obtained at 1 millisievert (mSv) and reconstructed with filtered back projection (FBP) and adaptive statistical iterative reconstruction (ASIR) with those of half-dose CTE images for the evaluation of active inflammation in patients with Crohn's disease. METHODS: Forty-six consecutive patients (mean age 29 years; range 15-59 years) with Crohn's disease underwent CTE which comprised a standard-dose scan at the enteric phase (45 s), a half-dose scan with ASIR at the portal venous phase (70 s), and 1 mSv scans with FBP and ASIR at the delayed phase (90 s) under a fixed 120 kVp and variable mAs...
October 16, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/29037938/non-clostridium-difficile-bacterial-infections-are-rare-in-patients-with-flares-of-inflammatory-bowel-disease
#12
Yuri Hanada, Sahil Khanna, Edward V Loftus, Laura E Raffals, Darrell S Pardi
BACKGROUND & AIMS: Clostridium difficile infection (CDI) causes flares in patients with inflammatory bowel disease (IBD). We investigated the frequency and outcomes of non-CDI bacterial enteric infections in symptomatic patients with IBD. METHODS: We performed a retrospective study of patients with ulcerative colitis (UC) or Crohn's disease (CD) from whom stool samples were collected and analyzed by PCR or culture for bacterial pathogens (Campylobacter jejuni or C coli, Salmonella species, Shigella species, entero-invasive Escherichia coli, shiga toxin-producing E coli, or Yersinia species) from November 19, 2011, through June 30, 2014...
October 13, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29037795/the-burden-of-hospital-readmissions-among-pediatric-patients-with-inflammatory-bowel-disease
#13
Edward L Barnes, Bharati Kochar, Millie D Long, Christopher F Martin, Seth D Crockett, Joshua R Korzenik, Michael D Kappelman
OBJECTIVE: To evaluate the burden and predictors of hospital readmissions among pediatric patients with inflammatory bowel disease using the Nationwide Readmissions Database. STUDY DESIGN: We performed a retrospective cohort study using 2013 Nationwide Readmissions Database. International Classification of Diseases, Ninth Revision, Clinical Modification codes were used to identify patients <18 years with diagnoses of ulcerative colitis (UC) or Crohn's disease (CD)...
October 13, 2017: Journal of Pediatrics
https://www.readbyqxmd.com/read/29037747/advancement-flap-technique-for-anal-fistula-in-patients-with-crohn-s-disease-a-systematic-review-of-the-literature
#14
Virginia Rozalén, David Parés, Edward Sanchez, José Troya, Sandra Vela, Miguel Ángel Pacha, Marta Piñol, Joan-Francesc Julián
INTRODUCTION: Treatment for anal fistulas in patients with Crohn's disease is still challenging, even for the expert surgeon. The advancement flap technique is characterized by the preservation of the anal sphincter complex. METHODS: A systematic review of the literature, selecting series of patients affected by Crohn's disease and anal fistulas and treated using advancement flap technique was performed. Patients followed during at least 6 months have been included...
October 13, 2017: Cirugía Española
https://www.readbyqxmd.com/read/29036010/the-reasoning-beyond-the-potential-use-of-exclusive-enteral-nutrition-and-other-specified-diets-in-children-with-ulcerative-colitis
#15
Ron Shaoul, Stephanie Brown, Andrew S Day
The incidence of inflammatory bowel disease (IBD) is steadily on the rise in Western as well as in developing countries paralleling the increase of westernized diets, characterized by high protein and fat as well as excessive sugar intake, with less vegetables and fiber. Furthermore, nutrition is involved in several aspects of pediatric inflammatory bowel disease (IBD), ranging from disease etiology to induction and maintenance of remission of disease. Exclusive enteral nutrition (EEN) has been shown to induce remission, including in patients with isolated colonic disease, and leads to mucosal healing in Crohn disease (CD)...
October 13, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29035182/induction-with-infliximab-and-a-plant-based-diet-as-first-line-ipf-therapy-for-crohn-disease-a-single-group-trial
#16
Mitsuro Chiba, Tsuyotoshi Tsuji, Kunio Nakane, Satoko Tsuda, Hajime Ishii, Hideo Ohno, Kenta Watanabe, Mai Ito, Masafumi Komatsu, Takeshi Sugawara
BACKGROUND: Approximately 30% of patients with Crohn disease (CD) are unresponsive to biologics. No previous study has focused on a plant-based diet in an induction phase of CD treatment. OBJECTIVE: To investigate the remission rate of infliximab combined with a plant-based diet as first-line (IPF) therapy for CD. METHODS: This was a prospective single-group trial conducted at tertiary hospitals. Subjects included consecutive adults with a new diagnosis (n = 26), children with a new diagnosis (n = 11), and relapsing adults (n = 9) with CD who were naïve to treatment with biologics...
2017: Permanente Journal
https://www.readbyqxmd.com/read/29034981/review-article-the-gut-microbiome-in-inflammatory-bowel-disease-avenues-for-microbial-management
#17
REVIEW
J McIlroy, G Ianiro, I Mukhopadhya, R Hansen, G L Hold
BACKGROUND: The concept of an altered collective gut microbiota rather than identification of a single culprit is possibly the most significant development in inflammatory bowel disease research. We have entered the "omics" era, which now allows us to undertake large-scale/high-throughput microbiota analysis which may well define how we approach diagnosis and treatment of inflammatory bowel disease (IBD) in the future, with a strong steer towards personalised therapeutics. AIM: To assess current epidemiological, experimental and clinical evidence of the current status of knowledge relating to the gut microbiome, and its role in IBD, with emphasis on reviewing the evidence relating to microbial therapeutics and future microbiome modulating therapeutics...
October 16, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29034305/fecal-zonulin-is-elevated-in-crohn-s-disease-and-in-cigarette-smokers
#18
Karin Malíčková, Irena Francová, Milan Lukáš, Martin Kolář, Eva Králíková, Martin Bortlík, Dana Ďuricová, Lenka Štěpánková, Kamila Zvolská, Alexandra Pánková, Tomáš Zima
OBJECTIVES: Human zonulin is a protein that increases permeability in the epithelial layer of the small intestine by reversibly modulating the intercellular tight junctions. There is not sufficient information available about zonulin's participation in inflammatory bowel diseases (IBD). The aim of this study was therefore to investigate fecal and serum zonulin in IBD patients and its relation to the disease localization, behavior and smoking status. DESIGN AND METHODS: Forty IBD patients and forty healthy persons were examined for fecal and serum zonulin concentrations by competitive ELISA (DRG International Inc)...
December 2017: Pract Lab Med
https://www.readbyqxmd.com/read/29033577/are-adipocytokines-inflammatory-or-metabolic-mediators-in-patients-with-inflammatory-bowel-disease
#19
Resul Kahraman, Turan Calhan, Abdurrahman Sahin, Kamil Ozdil, Zuhal Caliskan, Elif Sinem Bireller, Bedia Cakmakoglu
This study examined the adiponectin and leptin levels and insulin resistance (IR) in patients with inflammatory bowel disease (IBD) and the associations between these factors and IBD characteristics. Fasting serum leptin, adiponectin, glucose, and insulin levels, as well as inflammatory parameters, were measured in 105 patients with IBD (49 patients with Crohn's disease [CD], 56 patients with ulcerative colitis [UC]) and 98 healthy controls [HC]. IR was evaluated using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29032767/metabonomics-uncovers-a-reversible-proatherogenic-lipid-profile-during-infliximab-therapy-of-inflammatory-bowel-disease
#20
Jacob Tveiten Bjerrum, Casper Steenholdt, Mark Ainsworth, Ole Haagen Nielsen, Michelle Ac Reed, Karen Atkins, Ulrich Leonhard Günther, Fuhua Hao, Yulan Wang
BACKGROUND: One-third of inflammatory bowel disease (IBD) patients show no response to infliximab (IFX) induction therapy, and approximately half of patients responding become unresponsive over time. Thus, identification of potential treatment response biomarkers are of great clinical significance. This study employs spectroscopy-based metabolic profiling of serum from patients with IBD treated with IFX and healthy subjects (1) to substantiate the use of spectroscopy as a semi-invasive diagnostic tool, (2) to identify potential biomarkers of treatment response and (3) to characterise the metabolic changes during management of patients with tumour necrosis factor-α inhibitors...
October 16, 2017: BMC Medicine
keyword
keyword
4025
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"